NASDAQ:XRTX XORTX Therapeutics (XRTX) Stock Price, News & Analysis $2.08 -0.04 (-1.70%) As of 11:35 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipTrendsBuy This Stock About XORTX Therapeutics Stock (NASDAQ:XRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XORTX Therapeutics alerts:Sign Up Key Stats Today's Range$2.07▼$2.1450-Day Range$2.01▼$2.4052-Week Range$1.73▼$7.05Volume1,858 shsAverage Volume547,363 shsMarket Capitalization$3.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd. Read More XORTX Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreXRTX MarketRank™: XORTX Therapeutics scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingXORTX Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXORTX Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about XORTX Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of XORTX Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XORTX Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXORTX Therapeutics has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about XORTX Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.47% of the float of XORTX Therapeutics has been sold short.Short Interest Ratio / Days to CoverXORTX Therapeutics has a short interest ratio ("days to cover") of 1.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XORTX Therapeutics has recently decreased by 5.68%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXORTX Therapeutics does not currently pay a dividend.Dividend GrowthXORTX Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.58 News SentimentXORTX Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for XORTX Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added XORTX Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XORTX Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.90% of the stock of XORTX Therapeutics is held by insiders.Percentage Held by Institutions0.23% of the stock of XORTX Therapeutics is held by institutions.Read more about XORTX Therapeutics' insider trading history. Receive XRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XORTX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XRTX Stock News HeadlinesXORTX Therapeutics Inc.: XORTX Announces Director ResignationAugust 1 at 7:00 AM | finanznachrichten.deXORTX Announces Director ResignationJuly 31 at 5:30 PM | financialpost.comFThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.August 3 at 1:00 AM | Chaikin Analytics (Ad)XORTX Announces Director ResignationJuly 31 at 5:00 PM | globenewswire.comXORTX Therapeutics Adds Independent Director to Strengthen Board OversightJuly 29, 2026 | tipranks.comXORTX Appoints New DirectorJuly 29, 2026 | financialpost.comFXORTX Appoints New DirectorJuly 29, 2026 | globenewswire.comXORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEOJune 15, 2026 | financialpost.comFSee More Headlines XRTX Stock Analysis - Frequently Asked Questions How have XRTX shares performed this year? XORTX Therapeutics' stock was trading at $2.81 at the beginning of 2026. Since then, XRTX stock has decreased by 26.0% and is now trading at $2.08. How were XORTX Therapeutics' earnings last quarter? XORTX Therapeutics Inc. (NASDAQ:XRTX) released its earnings results on Saturday, May, 16th. The technology company reported ($0.58) earnings per share (EPS) for the quarter. When did XORTX Therapeutics' stock split? Shares of XORTX Therapeutics reverse split on Monday, April 6th 2026.The 1-5 reverse split was announced on Wednesday, April 1st 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of XORTX Therapeutics? Shares of XRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XORTX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that XORTX Therapeutics investors own include NVIDIA (NVDA), Aptorum Group (APM), Avalo Therapeutics (AVTX), Coya Therapeutics (COYA), Deswell Industries (DSWL), Dawson Geophysical (DWSN) and EUDA Health (EUDA). Company Calendar Last Earnings5/16/2026Today8/03/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (13m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 XRTX's financial health is in the Red zone, according to TradeSmith. XRTX has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:XRTX CIK1284823 Webwww.xyratex.com Phone+44-23-92496000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($2.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-150.01% Return on Assets-106.53% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book1.39Miscellaneous Outstanding Shares1,817,000Free Float1,692,000Market Cap$3.78 million OptionableNot Optionable Beta0.74 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:XRTX) was last updated on 8/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XORTX Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XORTX Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
